Nano-X Imaging Ltd., a development-stage company, develops, produces, and commercializes digital X-ray source technology for the medical imaging industry worldwide. Its X-ray source is based on a novel digital MEMs semiconductor cathode. The company also develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. Nano-X Imaging Ltd. was founded in 2011 and is headquartered in Neve Ilan, Israel.
IPO Year: 2020
Exchange: NASDAQ
Website: nanox.vision
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
Ladenburg Thalmann initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $52.00
Cantor Fitzgerald reiterated coverage of Nano X Imaging with a rating of Overweight and set a new price target of $67.00 from $70.00 previously
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be
First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play' installation processSystem design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Nanox.ARC X
ADOPT Study Findings Highlight Nanox.AI's Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study at four major upcoming medical conferences spanning March through June 2025. The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and
PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc
In a clinical study, it was found that the Nanox.ARC digital tomosynthesis enhanced musculoskeletal imaging, can improve the sensitivity and specificity of conventional radiography. In addition, can improve cast and metal imaging, eliminate the need for CT in some cases while at the same time reducing the patient radiation exposure and radiologist reading time.The Nanox.ARC outperformed standard x-ray in detecting lung nodules under simulated obesity conditions in phantoms PETACH TIKVA, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will present data sup
CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S.New clinical data supporting use of Nanox.ARC to be presented at European Congress of Radiology (ECR) 2025.Nanox.ARC is an FDA, CE Marked, digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization.Nanox.ARC unlocks significant value for medical practices, providers, and their patients. PETACH TIKVA, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received CE (Conformi
Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication for the musculoskeletal systemNanox.ARC uses high voltage powered digital X-ray tubes for 3D tomosynthesis imaging that could help expand availability of medical imagingNanox.ARC now deployed at healthcare facilities across seven states in the U.S. PETACH TIKVA, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and D
Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 Earnings Call Registration. You may access the live webcast of the conference ca
Nanox AI's Solutions selected for Special Mention on annual list recognizing the most impactful new products and ideas PETACH TIKVA, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, NanoxAI Ltd. (Nanox AI), was selected for a Special Mention in the TIME's Best Inventions of 2024 list. TIME's annual Best Inventions list celebrates the most groundbreaking products and ideas that are shaping industries and enhancing lives. As noted by TIME, Nanox AI was highlighted as one of the most impactful new products, using
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
20-F - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be
PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc
Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023
PETACH TIKVA, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2024, before market open on Thursday, November 21, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 Earnings Call Registration. You may access the live webcast of the conference ca
PETACH TIKVA, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2024, before market open on Tuesday, August 20, 2024. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q2 Earnings Call Registration. You may access the live webcast of the conference call by u
PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2024, before market open on Tuesday, May 28, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 Earnings Call Registration. You may access the live webcast of the conference call by using the following link
PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. You may access the live webcast of the conference call by usi
NEVE ILAN, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2023 on November 28, 2023 at 8:30 a.m. ET. The Company also announced that it will hold its Investor Day on December 4, 2023, at the Nasdaq building in New York City. Earnings Call Information Interested parties may register for the conference call using the following link: https://register.vevent.com/register/BI7080cf9036fa460db045f1becd1a1cf1 You may access the live webcast of the conference call by using the following link: https:
NEVE ILAN, Israel, May 17, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company, ", NASDAQ:NNOX) will report its financial results for the first quarter ended March 31, 2023 before market on Monday, May 22, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2023 Earnings Registration Link. You may access the live webcast of the conference call by using the following link: Nanox Q1 2023 Earnings. Both links will be posted in the Investor
NANO-X IMAGING LTD ((", Nanox", or the ", Company, ", NASDAQ:NNOX) will report its financial results for the fourth quarter ended December 31, 2022 before market on Thursday, March 9, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2022 Earnings Registration Link. You may access the live webcast of the conference call by using the following link: Nanox Q4 2022 Earnings. The link will also be posted in the Investor Relations section of the Nanox website at